

The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis.

NCT07069725

Status	RECRUITING
Phase	Phase 1
Sponsor	AstraZeneca
Enrollment	12 participants

Key Eligibility Criteria

Inclusion (4)

- Male or female (of non-childbearing potential) participant aged ≥ 20 years and willing and able to give written informed consent for participation in the trial.
- History confirming compensated liver cirrhosis.
- Females must have a negative pregnancy test.
- Barrier contraceptives use by males.

Exclusion (10)

- A condition that would interfere with evaluation of the trial intervention, put the participant at risk, influence the participant's ability to participate or affect the interpretation of the results of the trial.
- Any clinically significant illness, medical or major surgical procedure or trauma prior randomization.
- Hepatitis B , hepatitis C and/or HIV infection.
- Significant elevations in liver blood test, MELD score >12 and platelets $<100 \times 10^9/L$ g).
- eGFR) $< 60 \text{ ml/min/1.73m}^2$.
- ... and 5 more (see full listing online)

Locations (2 total)

Research Site, Solna, Sweden
Research Site, Stockholm, Sweden